ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 376

Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study

Okinori Murata1, Katsuya Suzuki 2, Nobuhito Sasaki 3, Tsutomu Takeuchi 2 and Makoto Maemondo 3, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 3Division of Pulmonary medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Lung Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with idiopathic interstitial pneumonia (IIP) may have features of connective tissue diseases (CTDs). The term interstitial pneumonia with autoimmune features (IPAF) has been recently proposed for such patients. Factors reported to indicate a poor prognosis in IPAF include age, smoking history, non-specific interstitial pattern in HRCT, anti-RNP antibody positivity, decline in %DLCO and presence of a multi-compartment feature within the morphological domain [1-3]. To date, however, no study has comprehensively described outcomes over a long-term period and factors of exacerbation. The aim of study was to identify prognostic factors for exacerbation in patients with IPAF, and compare long-term outcomes among patients with IPAF, IIP, and CTD-ILD.

Methods: Six hundreds- and seventy-two patients who visited our department between April 2009 and March 2019 and were evaluated by chest HRCT scan. Then, they were clinically and radiologically diagnosed as having interstitial lung disease (ILD), IIP or connective tissue diseases associated ILD were enrolled. We applied IPAF criteria to these patients and then purified 68 patients. The prognostic factors for exacerbation were prospectively calculated and statistically analyzed using clinical, laboratory and imaging data collected from medical records.

Results: Of 68 patients with IPAF, 60% were women and mean age at diagnosis was 64.2 ± 13.8 years old. Mean observation period was 27.1 ± 29.6 months. Exacerbation rate was 25% (n=17). Overall death rate was 5.9% (n=4). Comparison of characteristics at diagnosis between the exacerbation group and non-exacerbation group showed that the exacerbation group had a significantly elevated rate of smoking, KL-6, and SP-D (P=0.034, 0.016, and 0.007). When we compared characteristics at diagnosis between the treatment group and non-treatment group in patients with IPAF, and those between the exacerbation group and non-exacerbation group in IPAF patients with treatment, the treatment group was significantly associated with signs of mechanic’s hands, arthritis, anti-SS-A antibody positivity, and anti-ARS antibody positivity (P=0.009, 0.05, 0.05, and 0.007), and the exacerbation group in IPAF patients with treatment had a significantly elevated rate of smoking and KL-6 (P=0.008 and 0.019). When we compared long-term outcomes among patients with IPAF, IIP, and CTD-ILD, 5-year non-exacerbation rate in IPAF patients with treatment, those without treatment, CTD-ILD patients, and IIP patients was 36.5%, 83.3%, 59.5%, and 28.3%, respectively. (Figure 1)

Conclusion: Our large-scale cross-sectional cohort study identified unique prognostic factors of exacerbation and long-term outcome in patients with IPAF.
References: [1] BMC Pulmonary Medicine. (2017), [2] Eur Respir J. (2016), [3] Clin Rheumatol. (2018)


ACR2019 Abstract Figure

Figure 1. Kaplan-Meier survival curves of interstitial pneumonia with autoimmune features -IPAF- with or without treatment -n=38 and 30-, idiopathic pulmonary fibrosis -IIP- -n=170- and connective tissue disease -CTD–interstitial lung disease -ILD- -n=92-.


Disclosure: O. Murata, None; K. Suzuki, AbbVie, 2, Bristol-Myers Squibb, 2, Chugai, 2, Daiichi-Sankyo, 2, Eisai, 2, Fuji Film, 2, Kissei, 2, Mitsubishi Tanabe, 2, Ono, 2, Pfizer, 2, Takeda Pharmaceutical, 2; N. Sasaki, None; T. Takeuchi, Mitsubishi Tanabe Pharma Co., 2, 8, Mitsubishi Tanabe Pharma Corporation, 2, 5, 8; M. Maemondo, None.

To cite this abstract in AMA style:

Murata O, Suzuki K, Sasaki N, Takeuchi T, Maemondo M. Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/long-term-outcome-and-prognostic-factors-of-patients-with-interstitial-pneumonia-with-autoimmune-features-a-single-center-large-scale-observational-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-outcome-and-prognostic-factors-of-patients-with-interstitial-pneumonia-with-autoimmune-features-a-single-center-large-scale-observational-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology